Calculating the net clinical benefit in neuro-oncology clinical trials using two methods: quality-adjusted survival effect sizes and joint modeling.
Marijke B CoomansLinda DirvenNeil K AaronsonBrigitta G BaumertMartin van den BentAndrew BottomleyAlba A BrandesOlivier ChinotCorneel CoensThierry GorliaUlrich HerrlingerFlorence Keime-GuibertAnnika MalmströmFrancesca MartinelliJeff A SloanRoger StuppAndrea TalacchiMichael WellerWolfgang WickJaap C ReijneveldMartin J B TaphoornPublished in: Neuro-oncology advances (2020)
Both methods resulted in different outcomes, but adjusting for the impact of treatment on HRQoL resulted in theoretically reduced survival benefits.